PRP Regulatory Progress – Canada

Genus (LSE: GNS), a leading global animal genetics company, announces the following update in relation to its innovative PRRS1 Resistant Pig ("PRP") programme.

Genus is pleased to announce that Canada has approved use of the PRP gene edit. This approval follows years of close collaboration with multiple Canadian regulatory agencies and represents another important step towards PRP commercialisation in North America. Genus believes successful commercialisation of PRP in North America requires further approvals in key North American export markets, particularly Mexico and Japan. The Group continues to make progress with regulators in these jurisdictions as well as with other international regulators, including China.

PRRS is one of the most devastating global pig diseases and causes suffering and premature death for pigs. A 2024 study from Iowa State University2 estimated the cost of PRRS to be $1.2 billion per annum in the U.S. alone and a separate study indicated that PRRS increased antibiotic usage by more than 200%3.

The information contained within this announcement is deemed by Genus to constitute inside information as stipulated under the Market Abuse Regulation (EU) no. 596/2014 (as incorporated into UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). On the publication of this announcement via a regulatory information service, this inside information is now considered to be in the public domain.

Notes

1 Porcine Reproductive and Respiratory Syndrome

2 https://research.iastate.edu/2024/07/30/growing-losses-from-prrs-cost-pork-producers-1-2-billion-per-year-new-study-shows/

3 https://dr.lib.iastate.edu/entities/publication/4e3cd302-5ae9-4185-8ead-405e0d4ec2f2